Related Experiment Video

Updated: Jul 3, 2025

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.2K

Pyrazole Scaffold: Potential PTP1B Inhibitors for Diabetes Treatment

Kishor R Danao1, Vijayshri V Rokde1, Deweshri M Nandurkar1

  • 1Department of Pharmaceutical Chemistry, Dadasaheb Balpande College of Pharmacy, Nagpur, Maharashtra 440037, India.

Current Diabetes Reviews
|February 14, 2024
PubMed
Abstract

Insights

Pyrazole scaffolds show significant potential for inhibiting Protein Tyrosine Phosphatase 1B (PTP1B), a key factor in diabetes and obesity. This research highlights pyrazole derivatives as promising therapeutic agents for metabolic disorders.

Area of Science:

  • Medicinal Chemistry
  • Pharmacology
  • Biochemistry

Background:

  • Protein Tyrosine Phosphatase 1B (PTP1B) overexpression is linked to insulin resistance, type 2 diabetes (T2DM), and obesity.
  • PTP1B negatively regulates insulin and leptin signaling pathways, making it a therapeutic target.
  • The pyrazole scaffold possesses diverse pharmacological properties of pharmaceutical interest.

Purpose of the Study:

  • To review the significance of the pyrazole scaffold in medicinal chemistry.
  • To examine the role of PTP1B in diabetes and obesity.
  • To explore the therapeutic potential of pyrazole derivatives in treating T2DM.

Main Methods:

  • Comprehensive literature review across major scientific databases (Web of Science, PubMed, ResearchGate, ScienceDirect).
  • Classification and analysis of published studies on pyrazole derivatives and PTP1B inhibition.
  • In silico analysis of pyrazole scaffold interactions with PTP1B amino acid residues.

Main Results:

  • Various pyrazole derivatives demonstrated significant PTP1B inhibitory activity.
  • Specific derivatives, including those with oxadiazole, rhodanine, triazine, indole, and fluorophenyl groups, showed notable inhibition.
  • In silico studies revealed pyrazole scaffold interactions with key amino acid residues (e.g., TYR46, ASP48, PHE182).

Conclusions:

  • PTP1B is a critical target for managing diabetes and obesity.
  • Pyrazole derivatives exhibit considerable potential as PTP1B inhibitors.
  • The pyrazole scaffold represents a promising therapeutic strategy for T2DM and obesity.
Keywords:
DiabetesPTP1BT2DMinsulinpyrazolepyrazole scaffold.

More Related Videos

Microwave-Assisted Preparation of 1-Aryl-1H-pyrazole-5-amines05:07

Microwave-Assisted Preparation of 1-Aryl-1H-pyrazole-5-amines

Published on: June 23, 2019

6.7K
Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay05:17

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Published on: February 9, 2021

1.5K

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
187
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
201
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
322
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
208
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
154
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
175